The Prof G Pod with Scott Galloway

Podbit · The Prof G Pod with Scott Galloway

Why People Are Losing Faith in Healthcare

Explore episode Jun 4, 2026

Where this was said

AI in Drug Discovery: Overhyped for Now, Transformative in a Decade

At 37:05 · chapter starts 36:55

Jensen Huang's vision of AI as the engine of a 'great age of discovery' in biotech gets a reality check from the CEO of the world's most valuable pharma company. Ricks is not dismissive — Lilly scientists use OpenAI and Anthropic tools daily and he's working with NVIDIA to build better biological datasets. But he draws a sharp distinction: LLMs excel at synthesizing the totality of human written knowledge, and they're good at it because that knowledge base is nearly complete. Biology isn't. Humans have mapped perhaps 10–20% of how the human body actually works, which means training an AI on it produces models that are 'terrible at predicting' outcomes in the remaining 80%. The second limitation: drug discovery ultimately requires physical experimentation. Tirzepatide was the 700th formulation tested — and the 20 of roughly 1,000 preclinical steps that Lilly has automated with AI or machine learning still leave 980 to go. The human experimentation phase — clinical trials — can't be shortcut by AI for the foreseeable future. His estimate: five to seven years before AI meaningfully reduces laboratory experiments, and a full ten-year arc before it genuinely accelerates drug discovery at scale.

Similar podbits